Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller aims to prevent gut woes after brain surgery

NCT ID NCT07650812

Symptom relief Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called oliceridine can reduce stomach and bowel problems after brain surgery. About 176 adults having brain tumor removal will receive either oliceridine or a standard opioid during surgery. The goal is to see if oliceridine lowers the risk of nausea, vomiting, and constipation, which can be dangerous after neurosurgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oliceridine
What this could lead to
If it works, this could offer a way to reduce nausea, vomiting, and constipation after brain surgery, potentially lowering the risk of bleeding.
What could go wrong
This is a small, early-stage trial that hasn't started yet. The benefit over standard opioids is unproven, and oliceridine may still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 176 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing selective neurosurgical resection of craniocerebral tumors; * Age ≥ 18 years old; * American Society of Anesthesiologists (ASA) grade 1-3; * Sign the informed consent form. Exclusion Criteria: * Patients unable to complete scale assessment due to preoperative language dysfunction or communication impairment; * Patients with preoperative symptoms of posterior cranial nerve injury and who need to retain a tracheal tube; * Patients with insular, brainstem, or medullary lesions that may impair early postoperative recovery of consciousness; * Patients undergoing intracranial lesion resection via the transsphenoidal approach; * Patients with a history of previous abdominal surgery; * Patients with BMI \> 35.0 kg/m2; * Patients with liver or kidney dysfunction; * Patients with a history of allergic or adverse reactions to the test drug; * Patients with a history of drug abuse; * Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.